{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:48:46Z","timestamp":1764510526734},"reference-count":119,"publisher":"Cambridge University Press (CUP)","issue":"S3","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":2136,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2009]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The common occurrence and high level of morbidity and burden associated with social anxiety disorder (SAD) are gaining widespread recognition. Interest in understanding and treating the disorder has also grown in response to large-scale investigations that have demonstrated high levels of efficacy with both pharmacologic and nonpharmacologic treatments. Such trials indicate that many patients with generalized SAD (roughly 40% to 60%) respond (eg, Clinical Global Impressions\u2013Improvement rating 1 or 2) after an adequate treatment trial, despite having suffered with disabling symptoms for most of their adult lives. First-line therapy options include the selective serotonin reuptake inhibitors and the dual-acting serotonin-norepinephrine reuptake inhibitor venlafaxine. Second-line options consist of anticonvulsants (gabapentin, pregabalin, valproic acid) and benzodiazepines (clonazepam). Reversible and irreversible monoamine oxidase inhibitors (moclobemide and phenelzine, respectively), while effective, are not widely used. Nonpharmacologic approaches, such as cognitive-behavioral therapy (CBT), are also effective for SAD. Newer treatment strategies such as levetiracetam, atypical antipsychotics, or D-cycloserine in combination with CBT appear promising but require further investigation. Finding a well-tolerated, safe, and effective treatment for each individual patient is crucial as most will require ongoing treatment in order to maintain benefits, prevent SAD relapse, and to experience optimal outcomes in the long term.<\/jats:p>","DOI":"10.1017\/s1092852900027267","type":"journal-article","created":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T10:05:14Z","timestamp":1449050714000},"page":"24-33","source":"Crossref","is-referenced-by-count":15,"title":["Recent Advances in Understanding and Treating Social Anxiety Disorder"],"prefix":"10.1017","volume":"14","author":[{"given":"Herman G. M.","family":"Westenberg","sequence":"first","affiliation":[]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"key":"S1092852900027267_ref075","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200207000-00002"},{"key":"S1092852900027267_ref116","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.11.011"},{"key":"S1092852900027267_ref057","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244762"},{"key":"S1092852900027267_ref043","first-page":"217","volume-title":"Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"S1092852900027267_ref035","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.671"},{"key":"S1092852900027267_ref020","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.05.022"},{"key":"S1092852900027267_ref003","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1996.01830020077009"},{"key":"S1092852900027267_ref103","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2007.00546.x"},{"key":"S1092852900027267_ref082","unstructured":"Remeron [package insert]. West Orange, NJ: Organon, Inc; 2005."},{"key":"S1092852900027267_ref067","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.176.4.379"},{"key":"S1092852900027267_ref053","doi-asserted-by":"publisher","DOI":"10.1002\/da.20014"},{"key":"S1092852900027267_ref015","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.629"},{"key":"S1092852900027267_ref010","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.5.613"},{"key":"S1092852900027267_ref112","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0420b"},{"key":"S1092852900027267_ref077","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199708000-00003"},{"key":"S1092852900027267_ref038","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0349-8"},{"key":"S1092852900027267_ref022","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1176\/ajp.147.2.217","article-title":"Anxiety disorders in patients with Parkinson\u2019s disease","volume":"147","author":"Stein","year":"1990","journal-title":"Am J Psychiatry"},{"key":"S1092852900027267_ref044","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.175.2.120"},{"key":"S1092852900027267_ref034","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-4-30"},{"key":"S1092852900027267_ref071","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.55.12.1133"},{"key":"S1092852900027267_ref005","doi-asserted-by":"publisher","DOI":"10.1177\/0020764004043131"},{"key":"S1092852900027267_ref058","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1176\/ajp.156.5.756","article-title":"Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study","volume":"156","author":"Stein","year":"1999","journal-title":"Am J Psychiatry"},{"key":"S1092852900027267_ref042","doi-asserted-by":"publisher","DOI":"10.1159\/000414022"},{"key":"S1092852900027267_ref091","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810340070009"},{"key":"S1092852900027267_ref114","first-page":"48","article-title":"The Brief Social Phobia Scale","volume":"52","author":"Davidson","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"S1092852900027267_ref085","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000117423.05703.e7"},{"key":"S1092852900027267_ref048","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.2.275"},{"key":"S1092852900027267_ref033","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.05.043"},{"key":"S1092852900027267_ref113","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2007.06.027"},{"key":"S1092852900027267_ref059","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1999.tb10845.x"},{"key":"S1092852900027267_ref102","doi-asserted-by":"publisher","DOI":"10.1002\/da.1077"},{"key":"S1092852900027267_ref089","first-page":"169","article-title":"Valproic acid for the treatment of social anxiety disorder","volume":"18","author":"Kinrys","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"S1092852900027267_ref061","doi-asserted-by":"publisher","DOI":"10.1002\/da.10096"},{"key":"S1092852900027267_ref004","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.593"},{"key":"S1092852900027267_ref111","doi-asserted-by":"publisher","DOI":"10.1177\/026988110201600412"},{"key":"S1092852900027267_ref088","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n1213"},{"key":"S1092852900027267_ref070","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.49.4.290"},{"key":"S1092852900027267_ref064","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.2.190"},{"key":"S1092852900027267_ref052","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000106222.36344.96"},{"key":"S1092852900027267_ref028","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.11.1027"},{"key":"S1092852900027267_ref030","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.01.044"},{"key":"S1092852900027267_ref024","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.3.457"},{"key":"S1092852900027267_ref023","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n1203"},{"key":"S1092852900027267_ref027","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.08.012"},{"key":"S1092852900027267_ref078","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000270088.09415.6f"},{"key":"S1092852900027267_ref076","doi-asserted-by":"publisher","DOI":"10.1016\/0924-977X(92)90032-4"},{"key":"S1092852900027267_ref069","unstructured":"Zoloft [package insert]. New York, NY: Pfizer Pharmaceuticals; 2006."},{"key":"S1092852900027267_ref051","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000104906.75206.8b"},{"key":"S1092852900027267_ref047","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.179.1.23"},{"key":"S1092852900027267_ref007","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.04.002"},{"key":"S1092852900027267_ref106","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2007.0007"},{"key":"S1092852900027267_ref104","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.02.025"},{"key":"S1092852900027267_ref084","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199908000-00010"},{"key":"S1092852900027267_ref118","doi-asserted-by":"publisher","DOI":"10.1016\/0005-7967(89)90093-4"},{"key":"S1092852900027267_ref110","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200012000-00009"},{"key":"S1092852900027267_ref068","unstructured":"Paxil [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2002."},{"key":"S1092852900027267_ref109","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199810000-00004"},{"key":"S1092852900027267_ref006","first-page":"3","article-title":"Overview of key data from the European Study of the Epidemiology of Mental Disorders (ESEMeD)","volume":"68","author":"Alonso","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"S1092852900027267_ref018","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1049-7"},{"key":"S1092852900027267_ref079","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000186871.04984.8d"},{"key":"S1092852900027267_ref032","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.03.029"},{"key":"S1092852900027267_ref083","unstructured":"Serzone [package insert]. Princeton, NJ: Bristol-Myers Squibb, Co; 1998."},{"key":"S1092852900027267_ref045","first-page":"113","volume-title":"Handbook of Psychiatric Measures","author":"Sheehan","year":"2000"},{"key":"S1092852900027267_ref066","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-1957-9"},{"key":"S1092852900027267_ref087","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0909"},{"key":"S1092852900027267_ref117","doi-asserted-by":"publisher","DOI":"10.1101\/lm.78204"},{"key":"S1092852900027267_ref001","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2000"},{"key":"S1092852900027267_ref108","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n1009"},{"key":"S1092852900027267_ref016","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291799008375"},{"key":"S1092852900027267_ref092","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-6185(00)00027-X"},{"key":"S1092852900027267_ref098","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0415"},{"key":"S1092852900027267_ref002","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291707001699"},{"key":"S1092852900027267_ref012","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.3.251"},{"key":"S1092852900027267_ref050","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1176\/ajp.152.9.1368","article-title":"Sertraline for social phobia: a double-blind, placebo-controlled crossover study","volume":"152","author":"Katzelnick","year":"1995","journal-title":"Am J Psychiatry"},{"key":"S1092852900027267_ref041","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.8.708"},{"key":"S1092852900027267_ref081","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200211000-00008"},{"key":"S1092852900027267_ref014","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2003.09.002"},{"key":"S1092852900027267_ref025","doi-asserted-by":"publisher","DOI":"10.1002\/da.20268"},{"key":"S1092852900027267_ref026","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1176\/ajp.154.2.239","article-title":"Dopamine reuptake site densities in patients with social phobia","volume":"154","author":"Tiihonen","year":"1997","journal-title":"Am J Psychiatry"},{"key":"S1092852900027267_ref062","first-page":"CD001206","volume-title":"Cochrane Database Syst Rev","author":"Stein","year":"2004"},{"key":"S1092852900027267_ref093","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n0405"},{"key":"S1092852900027267_ref101","doi-asserted-by":"publisher","DOI":"10.1002\/da.10112"},{"key":"S1092852900027267_ref119","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519050-00002"},{"key":"S1092852900027267_ref021","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.045518"},{"key":"S1092852900027267_ref095","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.5.425"},{"key":"S1092852900027267_ref008","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.8.903"},{"key":"S1092852900027267_ref094","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291707000918"},{"key":"S1092852900027267_ref100","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(96)00030-4"},{"key":"S1092852900027267_ref099","first-page":"244","article-title":"Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder","volume":"65","author":"Seedat","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"S1092852900027267_ref017","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300004"},{"key":"S1092852900027267_ref019","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.07.006"},{"key":"S1092852900027267_ref031","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200502080-00024"},{"key":"S1092852900027267_ref090","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199312000-00008"},{"key":"S1092852900027267_ref055","doi-asserted-by":"publisher","DOI":"10.1177\/0269881106065102"},{"key":"S1092852900027267_ref097","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.61.10.1005"},{"key":"S1092852900027267_ref074","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.172.1.70"},{"key":"S1092852900027267_ref105","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.61.11.1153"},{"key":"S1092852900027267_ref046","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0213"},{"key":"S1092852900027267_ref065","doi-asserted-by":"publisher","DOI":"10.1002\/hup.602"},{"key":"S1092852900027267_ref036","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.1.85"},{"key":"S1092852900027267_ref049","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0708"},{"key":"S1092852900027267_ref037","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2004.02.070"},{"key":"S1092852900027267_ref009","doi-asserted-by":"publisher","DOI":"10.1080\/j.1440-1614.2006.01903.x"},{"key":"S1092852900027267_ref011","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.52.5.637"},{"key":"S1092852900027267_ref115","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.3.298"},{"key":"S1092852900027267_ref029","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2007.164.2.318"},{"key":"S1092852900027267_ref054","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.186.3.222"},{"key":"S1092852900027267_ref056","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200206000-00005"},{"key":"S1092852900027267_ref086","doi-asserted-by":"publisher","DOI":"10.1002\/hup.846"},{"key":"S1092852900027267_ref013","doi-asserted-by":"publisher","DOI":"10.1053\/comp.2002.33500"},{"key":"S1092852900027267_ref096","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.72.3.392"},{"key":"S1092852900027267_ref063","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000138764.31106.60"},{"key":"S1092852900027267_ref060","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0113"},{"key":"S1092852900027267_ref072","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.161.3.353"},{"key":"S1092852900027267_ref039","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.1.59"},{"key":"S1092852900027267_ref040","first-page":"54","article-title":"Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety","volume":"59","author":"Ballenger","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"S1092852900027267_ref080","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0215"},{"key":"S1092852900027267_ref107","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.12.1111"},{"key":"S1092852900027267_ref073","first-page":"71","article-title":"Moclobemide in social phobia. A double-blind, placebo-controlled clinical study","volume":"247","year":"1997","journal-title":"Eur Arch Psychiatry Clin Neurosci."}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852900027267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T20:43:41Z","timestamp":1718225021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852900027267\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":119,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2009]]}},"alternative-id":["S1092852900027267"],"URL":"https:\/\/doi.org\/10.1017\/s1092852900027267","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009]]}}}